Evidence map›Paper›PMID 33507962›Full record

ArticlePloS one2021

Modeling the relative risk of SARS-CoV-2 infection to inform risk-cost-benefit analyses of activities during the SARS-CoV-2 pandemic.

John E McCarthy, Barry D Dewitt, Bob A Dumas, Myles T McCarthy

Abstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Repurposing FDA-approved drugs to fight COVID-19 usingInformatics in medicine unlocked · 2021
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

John E McCarthyDepartment of Mathematics and Statistics, Washington University in St. Louis, Saint Louis, Missouri, United States of America.ORCID 0000-0003-0036-7606
Barry D DewittDepartment of Engineering & Public Policy, Carnegie Mellon University, Pittsburgh, PA, United States of America.ORCID 0000-0003-1622-6736
Bob A DumasOmnium LLC, Saint Joseph, MO, United States of America.
Myles T McCarthyUniversity of Illinois at Urbana-Champaign, Champaign, IL, United States of America.

Funding

PET Imaging of Neuroinflammation in Genetic Alzheimer's DiseaseR01AG052550 · NIA · WASHINGTON UNIVERSITY · PI Beau M Ances, Tammie Lee Smith Benzinger · 2018 to 2026
$4.2M
NIA NIH HHS R01 AG052550NIH HHS R01 AG052550-01A1
6 · The paper itself

Abstract

Risk-cost-benefit analysis requires the enumeration of decision alternatives, their associated outcomes, and the quantification of uncertainty. Public and private decision-making surrounding the COVID-19 pandemic must contend with uncertainty about the probability of infection during activities involving groups of people, in order to decide whether that activity is worth undertaking. We propose a model of SARS-CoV-2 infection probability that can produce estimates of relative risk of infection for diverse activities, so long as those activities meet a list of assumptions, including that they do not last longer than one day (e.g., sporting events, flights, concerts), and that the probability of infection among possible routes of infection (i.e., droplet, aerosol, fomite, and direct contact) are independent. We show how the model can be used to inform decisions facing governments and industry, such as opening stadiums or flying on airplanes; in particular, it allows for estimating the ranking of the constituent components of activities (e.g., going through a turnstile, sitting in one's seat) by their relative risk of infection, even when the probability of infection is unknown or uncertain. We prove that the model is a good approximation of a more refined model in which we assume infections come from a series of independent risks. A linearity assumption governing several potentially modifiable risks factors-such as duration of the activity, density of participants, and infectiousness of the attendees-makes interpreting and using the model straightforward, and we argue that it does so without significantly diminishing the reliability of the model.

Indexed as

AerosolsCost-Benefit AnalysisCOVID-19HumansModels, StatisticalModels, TheoreticalPandemicsReproducibility of ResultsRisk AssessmentRisk FactorsSARS-CoV-2Aerosols

Identifiers

PMID33507962
PMCPMC7842882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.